NDA 018508 · Baxter Hlthcare
Tis-U-Sol
Magnesium Sulfate, Potassium Chloride, Potassium Phosphate, Monobasic, Sodium Chloride, Sodium Phosphate · Irrigation
Last checked: Nov 20, 2026Latest source record: Jun 26, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1982
Feb 19, 1982
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
1
1 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 21, 2014.
INDICATIONS AND USAGE Isotonic solution for irrigation only. Not for injection.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 19, 1982 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- TIS-U-SOL · MAGNESIUM SULFATE 20MG/100ML; POTASSIUM CHLORIDE 40MG/100ML; POTASSIUM PHOSPHATE, MONOBASIC 6.25MG/100ML; SODIUM CHLORIDE 800MG/100ML; SODIUM PHOSPHATE 8.75MG/100ML · SOLUTION, IRRIGATION · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Tis-U-Sol" as an intervention, any sponsor and status, largest first.
- Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknown
Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityAcademic, hospital or other
NCT04870905 · 100 participants (planned) · Start Mar 1, 2023 · Primary completion May 1, 2024
Drug: Tis-U-Sol · For: Nasopharyngeal Neoplasms
Sites: Guangzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- abdominal distension1
- abnormal faeces1
- dehydration1
- device leakage1
- faeces discoloured1
- food intolerance1
- vomiting1
- wrong drug administered1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Baxter Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.